H.R. 2450 · Where this bill is now
In committee
Introduced in the House, sent to the Committee on Energy and Commerce, and in addition to the Committees on Education and Workforce, and Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned, Mar 27, 2025
What this bill does
In plain words · AI-written from the official summaryPharmacy managers report drug pricing data to insurers
This bill requires pharmacy benefit managers—companies that handle prescription drug claims for insurance plans—to share detailed information about drug prices and payments with the health insurance plans they work with. They'd have to report this data at least twice a year, showing things like the difference between what the insurer pays them and what they pay pharmacies, as well as rebates and discounts they receive from drug makers. Insurance plans would also have to share summary information with their members.
How it affects you
If you get health insurance through a large employer (100 or more employees), you'd gain access to more details about how much your plan is actually paying for prescription drugs and what fees are being charged. This transparency could help employers and workers understand drug pricing better, though the bill doesn't directly set prices or guarantee lower costs for you.
Read the official summary (Introduced in House, Mar 27, 2025)
Prescription Drug Transparency and Affordability Act
This bill requires pharmacy benefit managers (PBMs) to report, at least once every six months, prescription drug pricing, payment, and utilization data to the health insurance plans for which the PBM provides services.
Specifically, a PBM contracted to provide services to an employer or sponsor offering a large group health insurance plan (i.e., a plan with at least 100 employees or participants) must report to the plan certain information for prescription drug claims under the plan. This includes, for each drug, the difference between the compensation paid by the plan to the PBM and the compensation paid by the PBM to the pharmacy.
Further, for each therapeutic class of drugs under the plan, a PBM must report (1) the total amount it received in rebates, fees, and discounts; and (2) the net spending for each class after such rebates, fees, and discounts.
Each PBM also must report certain information about (1) drugs for which total spending exceeded $10,000; and (2) drugs dispensed through pharmacies affiliated with the plan or PBM, such as the percentage of prescriptions dispensed by such affiliates.
Finally, a PBM providing services to any group health insurance plan must provide the plan with a summary document that includes similar information for prescription drug claims under the plan, as determined by the Department of Health and Human Services. Plans must also make certain aggregate summary information available to plan participants.
PBMs and plans that violate these requirements are subject to civil penalties.
Written by AI (Claude) using only the official summary by the Congressional Research Service, the Library of Congress’s nonpartisan research staff. It can miss nuance, so check the official summary and the bill text for details.
1st SessionH. R. 2450
A BILL
Prescription Drug Transparency and Affordability Act
Sponsor: Rep. Kristen McDonald Rivet (D-MI-8) · Introduced Mar 27, 2025 · Health · 1 version of the text
Sources: Congress.gov actions and votes · bill text from GovInfo · latest official action Mar 27, 2025: “Referred to the Committee on Energy and Commerce, and in addition to the Committees on Education and Workforce, and Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.”